林普利塞治疗淋巴瘤临床应用指导原则

Guiding principles for clinical application of linperlisib in treatment of lymphoma

林普利塞是我国自主研发的1类新药,是我国首个上市的磷脂酰肌醇-3-激酶δ高选择性小分子抑制剂。2022年11月9日,林普利塞获得我国国家药品监督管理局批准用于既往接受过至少两种系统性治疗的复发或难治滤泡淋巴瘤成年患者。为更好地指导临床合理、有效、安全应用林普利塞,中国抗癌协会血液肿瘤专业委员会、中国临床肿瘤学会淋巴瘤专家委员会组织专家制定了该指导原则,以供临床医师参考。

Linperlisb is a class 1 new drug independently developed in China,which is also the first highly selective small molecule inhibitor targeting phosphatidylinositol 3-kinaseδlaunched in China.On November 9,2022,linperlisib was approved by the National Medical Products Administration for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two previous systemic therapies.To aid in the rational,safe and effective application of linperlisib in clinical practice,the Hematology Oncology Committee of Chinese Anti-Cancer Association and the Lymphoma Expert Committee of Chinese Society of Clinical Oncology organized experts to develop the following guiding principles for clinicians'reference.